Bacterial Biofilm Formation and its Implications for Chronic Infections: Therapeutic Strategies

Greub Morres^*
*Correspondence: Greub Morres, Department of Microbiology, University of Lausanne, Lausanne, Switzerland, Email:

Introduction

Bacterial biofilms, though microscopic in nature, wield a colossal impact on human health, particularly in the realm of chronic infections. These resilient communities of bacteria adhere to surfaces and encase themselves in a protective matrix, posing significant challenges to conventional treatment approaches. Understanding the dynamics of biofilm formation and devising effective therapeutic strategies are imperative in combating chronic infections. Bacterial biofilms represent an ingenious survival strategy adopted by various microbial species. The process begins with the reversible attachment of planktonic bacteria to a surface, followed by irreversible adhesion and proliferation. As the community matures, Extracellular Polymeric Substances (EPS) are synthesized, providing structural integrity and protection against external stressors, including antibiotics and the host immune system.

The three-dimensional architecture of biofilms creates microenvironments with heterogeneous nutrient and oxygen gradients, fostering the development of diverse bacterial phenotypes. This heterogeneity, coupled with the presence of persister cells—dormant variants resistant to antimicrobial agents—renders biofilms remarkably resilient. Biofilm formation is a complex process through which microbial communities adhere to surfaces and develop into structured multicellular aggregates encased within a self-produced Extracellular Matrix (ECM). This process occurs in various environments, including natural habitats such as soil, aquatic systems and medical settings like indwelling medical devices and human tissues [1,2]. Understanding the stages and mechanisms of biofilm formation is crucial for combating biofilm-related infections and addressing challenges in diverse fields ranging from healthcare to industrial biotechnology.

Description

The initial stage involves reversible attachment of planktonic (free-floating) microbial cells to a surface. This process is mediated by physical forces such as van der Waals interactions, electrostatic forces and hydrophobic interactions, as well as specific molecular interactions between microbial surface structures (e.g., pili, adhesins) and surface receptors. Following attachment, some microbial cells undergo irreversible adhesion, firmly anchoring them to the surface. This step involves the expression of adhesion molecules and the synthesis of adhesive extracellular polymers that strengthen the attachment to the substrate. Attached cells begin to proliferate and form microcolonies, initiating the development of three-dimensional structures. During this phase, quorum sensing—a cell-to-cell communication mechanism mediated by signaling molecules—plays a crucial role in coordinating gene expression and regulating biofilm development.

As the biofilm matures, microbial cells continue to multiply and the ECM undergoes extensive remodeling. The ECM, primarily composed of polysaccharides, proteins, extracellular DNA (eDNA) and lipids, provides structural support, protection against environmental stressors and facilitates nutrient and waste exchange within the biofilm community. In response to environmental cues or physiological triggers, biofilm-associated cells can detach from the biofilm and disseminate to colonize new surfaces or initiate planktonic growth [3,4]. Dispersal mechanisms include the active release of cells, enzymatic degradation of the ECM and programmed cell death (apoptosis). Chronic infections resulting from biofilm formation afflict millions worldwide, manifesting in various clinical scenarios. Examples include chronic wounds, recurrent urinary tract infections, prosthetic device-associated infections and cystic fibrosis-associated lung infections.

Biofilm-related infections often exhibit recalcitrance to antibiotic therapy, leading to prolonged illness, increased healthcare costs and heightened morbidity and mortality rates. The ability of biofilms to evade host immune responses further exacerbates the clinical severity of chronic infections. The EPS matrix acts as a physical barrier, hindering the penetration of immune effectors such as antibodies and phagocytes. Additionally, biofilm-associated bacteria can modulate host immune signaling pathways, dampening the inflammatory response and promoting immune tolerance. Addressing biofilm-associated chronic infections necessitates a multifaceted approach that targets both the microbial community and the host environment. Several promising therapeutic strategies have emerged, aiming to disrupt biofilm formation, enhance antimicrobial efficacy and bolster host immune responses.

Agents capable of disrupting the EPS matrix or inhibiting bacterial adhesion represent potential therapeutic avenues. Enzymes such as dispersin B and DNase have demonstrated efficacy in biofilm degradation, facilitating the dispersal of bacterial aggregates and enhancing susceptibility to antimicrobial agents. Combating biofilm-related infections often requires tailored antimicrobial regimens that account for the unique challenges posed by biofilm-associated bacteria. Combination therapies incorporating antibiotics, antimicrobial peptides, or bacteriophages can target different bacterial phenotypes and circumvent resistance mechanisms [5]. Augmenting host immune responses holds promise as an adjunctive therapy for biofilm-related infections. Immunomodulatory agents that enhance phagocytosis, cytokine production and neutrophil recruitment may overcome immune evasion strategies employed by biofilm-associated bacteria.

Conclusion

Bacterial biofilm formation represents a formidable obstacle in the treatment of chronic infections, posing significant clinical and therapeutic challenges. By elucidating the mechanisms underlying biofilm formation and persistence, researchers have identified promising therapeutic strategies to mitigate the impact of biofilm-related infections. A multidisciplinary approach integrating antimicrobial therapy, biofilm disruption strategies and host immune modulation holds the key to effectively managing chronic infections and improving patient outcomes in the era of antibiotic resistance. The development of innovative technologies, such as nanomaterial-based drug delivery systems and biofilm-targeted antimicrobial coatings, offers novel approaches to combat biofilm-related infections. These technologies aim to enhance drug penetration, prolong antimicrobial activity and prevent biofilm formation on medical devices and implant surfaces.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Cortese, Yvonne J., Victoria E. Wagner, Morgan Tierney and Declan Devine, et al. "Review of catheter-associated urinary tract infections and in vitro urinary tract models." J Healthc Eng 2018 (2018).

Google Scholar, Crossref, Indexed at

2. Melo, Luís DR, Patrícia Veiga, Nuno Cerca and Andrew M. Kropinski, et al. "Development of a phage cocktail to control Proteus mirabilis catheter-associated urinary tract infections." Front microbiol 7 (2016): 205312.

Google Scholar, Crossref, Indexed at

3. Adegun, Patrick Temi, Michael Simidele Odimayo, Julius Gbenga Olaogun and Eyitayo Ebenezer Emmanuel. "Comparison of uropathogens and antibiotic susceptibility patterns in catheterized ambulant middle-aged and elderly Nigerian patients with bladder outlet obstruction." Turk J Urol 45 (2019): 48.

Google Scholar, Crossref, Indexed at

4. Gaston, Jordan R., Marissa J. Andersen, Alexandra O. Johnson and Kirsten L. Bair, et al. "Enterococcus faecalis polymicrobial interactions facilitate biofilm formation, antibiotic recalcitrance, and persistent colonization of the catheterized urinary tract." Pathog 9 (2020): 835.

Google Scholar, Crossref, Indexed at

5. Letica-Kriegel, Allison S., Hojjat Salmasian, David K. Vawdrey and Brett E. Youngerman, et al. "Identifying the risk factors for catheter-associated urinary tract infections: A large cross-sectional study of six hospitals." BMJ Open 9 (2019): e022137.

Google Scholar, Crossref, Indexed at